Silexion Therapeutics Announces Exercise of Warrants
Key Highlights
- ➤Warrant exercise raises expected gross proceeds of $837,366.36 for Silexion Therapeutics (SLXN)
- ➤3,216,928 Series E warrants exercised immediately at reduced $0.2603 price
- ➤3,216,928 Series F warrants issued with five-year expiration after registration conditions
- ➤3,216,928 Series G warrants issued with 24-month expiration after registration conditions
- ➤Exercise price reduced to $0.2603 for all 3,846,161 outstanding Series E warrants
Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series E warrants to purchase up to an aggregate of 3,216,928 of the Company’s ordinary shares originally issued in August 2026 having a reduced exercise price of $0.2603 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-298137). The gross proceeds to the Company from the exercise of the warrants are expected to be $837,366.36, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about September 29, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.
Get started
Create a free account to read the full story.